A Cost Minimisation Analysis Of Cladribine Tablets Versus Alternative High Efficacy Treatments For Relapsing Multiple Sclerosis (RMS)

October 18, 2018 Danielle Twigg

In 2017, Cladribine Tablets (MAVENCLAD®) received its marketing authorization from the European Medicines Agency (EMA) for the treatment of patients with highly active relapsing multiple sclerosis (HA-RMS). In a Network Meta-Analysis (NMA) conducted by Siddiqui et al in 2017, the credible intervals for Cladribine Tablets, compared to alemtuzumab, fingolimod, and natalizumab, overlapped for key efficacy endpoints. Due to no statistical differences demonstrated in the NMA, the aim of this analysis was to assume comparable efficacy among these Disease Modifying Treatments (DMTs) and conduct a Cost Minimization Analysis (CMA) of Cladribine Tablets against these alternatives in a National Health Service (NHS) United Kingdom (U.K) setting.

Authors: Harty G, Treharne C, Budhia S, Wong SL

To find out more about this poster you can register to download it here after the ISPOR event.

Previous Article
A Review Of Recent Appraisals From The Institute For Clinical And Economic Review: How Important Is The ICER?
A Review Of Recent Appraisals From The Institute For Clinical And Economic Review: How Important Is The ICER?

Next Article
A Budget Impact Analysis Of Cladribine Tablets Versus Alternative High Efficacy Treatments For Relapsing Multiple Sclerosis (RMS) In The UK
A Budget Impact Analysis Of Cladribine Tablets Versus Alternative High Efficacy Treatments For Relapsing Multiple Sclerosis (RMS) In The UK